Get started

Wedgebreakout

USDCAD > What to Expect Next!?Analysis of #USDCAD The USDCAD might have reached its top, and now in the process of shifting trends, we could have a very valid sell setup as you can see the USDCAD broke out of the wedge pattern and now trading below its trendline support, which now become a trendline resistance. the market retested the trendline and now moving lower, if the daily candle closed below 1.3700 today, we have a confirmation, and this is a valid breakout if the market retreated and closes above 1.37500, this is a fake break, and better wait for better confirmation Thanks for your continued support!
Short
by TheTradersAvenue
19
GBP / USD Short IdeaBearish Chart pattern forming on 4h / 1h timeframe indicating a potential uptrend reversal which could retrace to the 0.382 Fibonacci Level and beyond. This trade idea offers an excellent 5+ Risk to Reward Ratio for the remainder of the week and due to the UK's troubles of tax, political unreasonableness and general economic horror i expect this resistance level once support to allow for big selling opportunity for people trying to reject the recent Bullish pullback on the Pound. - Note to never risk more than 1-3% of your account on any given trade. - Stop Loss 47 Pips above sell bracket. - Stop Loss is 76 Pips above entry point. Opinions on GBU / USD?
Short
by wozencroftkyle
Unilever (ULVR.l) bearish scenario:The technical figure Rising Wedge can be found in the daily chart in the UK company Unilever PLC (ULVR.l). Unilever plc is a British multinational consumer goods company. Unilever products include food, condiments, ice cream, cleaning agents, beauty products, and personal care. Unilever is the largest producer of soap in the world, and its products are available in around 190 countries. The Rising Wedge broke through the support line on 04/10/2022. If the price holds below this level, you can have a possible bearish price movement with a forecast for the next 31 days towards 3 647.00 GBp. Your stop-loss order, according to experts, should be placed at 4 178.00 GBp if you decide to enter this position. In the first half of 2022, Unilever's growth accelerated again as its robust sales in the U.S., India, and other markets easily offset its lockdown-induced disruptions in China. It also raised its prices to offset the impact of inflation. For the full year, it expects underlying sales to grow by more than 6.5%. Unilever's underlying earnings per share (EPS) rose 5.5% in 2021, but grew just 1% year-over-year in the first half of 2022 as the inflation and currency headwinds squeezed its margins. It expects its underlying operating margin to decline about 240 basis points to 16% this year. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
LSE:ULVRShort
by legacyFXofficial
AbbVie. Waiting for an exit from uptrendAbbVie Inc. Idea: Long Horizon: 1-2 months Target: $145 Entry range: $143-145 Stop order: $141 Technical analysis The share price has formed a short-term uptrend. If the local resistance level is broken through, there is a potential to move higher. Idea to increase the stock with the target of $145. Fundamental factor AbbVie is an American biopharmaceutical company founded in 2013 by a spinoff from Abbott Laboratories. One of the largest pharmaceutical companies in the world. Healthcare is a classic defensive sector in times of stock market turbulence. Given the high likelihood of continued serious tightening of monetary policy by the Fed, investors are shifting funds from interest-rate-dependent sectors to more stable ones. AbbVie's broadly diversified portfolio of drugs and products makes it one of the best candidates for this strategy.
NYSE:ABBVLong
by SiriusBH